Will Johnson & Johnson Stock Hit $300 This Year?

Quick Read

• JNJ has surged 55% implicit the past twelvemonth to $232.77, but hitting $300 by year-end demands a 29% summation and a 26x guardant P/E.

• Oncology drugs TREMFYA and RYBREVANT/LAZCLUZE surged implicit 68% successful Q1, portion talc litigation and STELARA biosimilar erosion drove nett income down 52%.

• Wall Street targets $253 for JNJ, but a DCF exemplary places intrinsic worth astatine $374, suggesting statement is underpricing the pipeline.

• It sounds nuts, but SoFi is giving new progressive put users up to $1,000 successful banal for a constricted time, and each it takes is simply a $50 deposit to get started. See for yourself (Sponsor)

Johnson & Johnson (NYSE:JNJ) has rallied 13.73% twelvemonth to day and 55.27% implicit the past year, fueled by oncology blockbusters and a MedTech franchise hitting connected each cylinder. CEO Joaquin Duato told investors that "Johnson & Johnson had a beardown commencement to 2026 and is delivering connected its committedness for a twelvemonth of accelerated maturation and impact."

The banal sits astatine $232.77. Can it propulsion to $300 earlier year-end?

What's Holding JNJ Back Right Now

Despite beardown gains, JNJ has cooled. Shares are up conscionable 3.3% implicit the past week and 4.23% implicit the past period aft a May pullback. Q1 2026 nett income fell 52.4% YoY, hammered by $330 cardinal successful litigation charges and 59.7% STELARA biosimilar erosion.

An FDA Early Alert connected Abiomed catheter kits and ongoing talc litigation grounds make overhang. With a beta of conscionable 0.256, JNJ seldom moves fast, truthful reaching $300 requires a wide catalyst to re-rate the aggregate higher.

Wall Street Sees 8.6% Upside. Our Model Says 12.2%

Consensus people sits astatine $252.87, with 5 Strong Buy, 10 Buy, 8 Hold, and 1 Strong Sell ratings. Our basal lawsuit lands astatine $261.05, for 12.15% upside, with a bull lawsuit astatine $252.64 and carnivore lawsuit astatine $227.36. Confidence connected that basal lawsuit is 90%.

SoFi Active Invest is offering a limited-time promotion. Open an account, money it with $50 oregon more, and you could person up to $1,000 in complimentary banal for Active Invest accounts. See for yourself by clicking present now.

With 63% of analysts bullish and a portfolio firing connected oncology and compartment therapy, the Street anchors connected the net dip alternatively than pipeline torque. Consensus is excessively cautious.

The Path to $300 Per Share

Reaching $300 from today's terms of $232.77 would necessitate a summation of 28.9%. With guardant EPS of $11.44, a terms of $300 implies a guardant P/E of 26x. Our basal lawsuit of $261.05 already implies 22x, meaning the bold people requires astir 4.5x further aggregate expansion.

Is that achievable? Yes, with conditions. The 1.099 247Factor already reflects antiaircraft assemblage momentum, debased volatility, and trading adjacent the 52-week high. Bullish catalysts are stacking up: DARZALEX grew 22.5%, TREMFYA jumped 68.3%, and RYBREVANT/LAZCLUZE surged 82.7% successful Q1.